Harvard Bioscience PE ratio HBIO

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 489×; Jul 2015
Peer median: 12.8×

Harvard Bioscience has no meaningful PE ratio today: it lost $2.31 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Jul 2015, at 489×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2015	489×	74.6×	489×
2014	103×	93.8×	103×
2013	143×	39.4×	145×
2012	46.1×	30.3×	48.1×

Against its peers

Companies in Healthcare nearest Harvard Bioscience's size, closest first, today.

Company	PE ratio
HBIOHarvard Bioscience	n/m
NEPHNephros	22.1×
ATNMActinium Pharmaceuticals	4.2×
APTAlpha Pro Tech	13.6×
SPROSpero Therapeutics	10.1×
LFVNLifevantage	14.7×
ICCCImmucell	128×
KEQUKewaunee Scientific	11.9×
PDEXPro DEX	15.1×
PLXProtalix BioTherapeutics	11.1×
NATRNatures Sunshine Products	12.0×
Peer median	12.8×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Harvard Bioscience

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.